BMS Has A Lot Of Ground To Make Up Ahead Of Patent Expiries
Opdivo Has Another Down Quarter
Bristol Myers Squibb is struggling to restore Opdivo’s growth and COVID-19 sales impacts didn’t help in Q1. New indications are coming but new products, like Zeposia, are slow to add significant revenue.
You may also be interested in...
BMS Sighs In Relief As Opdivo Returns To Sales Growth
With full-year 2020 and Q1 sales down due to pandemic, the company celebrates the PD-1 therapy’s growth in Q2. CAR-T products Breyanzi, Abecma are off to solid launches but face manufacturing hurdles.
BMS's Reblozyl Data Supports Adding Less Severe Patients To Label
Adding non-transfusion-dependent anemia patients to the Reblozyl label is a key strategy for the product, which BMS expects to reach $4bn in annual sales.
Merck & Co.'s Transitional Year Is Off To A Sluggish Start
The company, in the midst of a leadership and structural transition, said the pandemic negatively impacted revenues by about $600m.